Lanifibranor

Lanifibranor is a pharmaceutical compound currently under investigation for its potential therapeutic effects in the treatment of various fibrotic diseases and metabolic disorders. It is a pan-PPAR agonist, meaning it activates multiple subtypes of the PPAR family of nuclear receptors, specifically PPARα, PPARδ, and PPARγ.

Mechanism of Action

Lanifibranor works by modulating the activity of PPAR receptors, which play a crucial role in the regulation of lipid metabolism, glucose homeostasis, and inflammation. By activating these receptors, Lanifibranor can influence the expression of genes involved in these processes, potentially leading to therapeutic benefits in conditions characterized by metabolic dysfunction and fibrosis.

Clinical Development

Lanifibranor is being developed by the pharmaceutical company Inventiva. It is currently in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation and fibrosis. The drug has shown promise in preclinical studies and early-phase clinical trials, demonstrating the ability to reduce liver fat content, inflammation, and fibrosis.

Potential Indications

While the primary focus of Lanifibranor's development is for the treatment of NASH, its mechanism of action suggests potential utility in other fibrotic diseases and metabolic disorders, including:

• Systemic sclerosis
• Idiopathic pulmonary fibrosis
• Type 2 diabetes mellitus
• Dyslipidemia

Side Effects and Safety

As with any investigational drug, the safety profile of Lanifibranor is being closely monitored in clinical trials. Common side effects observed in early studies include gastrointestinal disturbances, weight gain, and edema. Long-term safety data will be crucial to determine the risk-benefit profile of the drug.

Conclusion

Lanifibranor represents a promising therapeutic candidate for the treatment of fibrotic diseases and metabolic disorders. Its unique mechanism of action as a pan-PPAR agonist offers a novel approach to modulating key pathways involved in these conditions. Ongoing clinical trials will provide further insights into its efficacy and safety.

See Also

• Peroxisome proliferator-activated receptor
• Non-alcoholic steatohepatitis
• Fibrosis
• Metabolic syndrome

External Links

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian